Valo SPAC Presentation Deck
Valo is a technology company built to transform drug discovery and
development using human-centric data and computation...
LEGACY BIOPHARMA MODEL ¹,2
Biological
DOC
ІНННННННН
Discovery
Ph II
------
Ph III
1-0-0-0-0-0-0-0-0-
Target
ID
DOC
Phl
Reg
1-0-0-0-0-0-0-0-0-| -0-0-0-0-0-0-0-0-
Target to
DOO
СНЕНННННН
Hit
Preclinical
ЕНЕННЕНТЕННЕН
Comm
Hit to
Lead
Lead Opt
LOCALIZED³ | DISINTEGRATED³
SURROGATE-DEPENDENT4 | SERIAL¹
VALO DRUG ACCELERATION MODEL 5
CLINICAL DEVELOPMENT
Reg
Comm
Phase
hase III
BIOLOGICAL
RWE
Diagnosis
Phase II
DISCOVERY
Target
Discovery
Opal
PLATFORM
Phase I
TM
Preclinical
Target ID
Target
to Hit
Lead Opt
Hit to
Lead
THERAPEUTIC DESIGN
UNIFIED INTEGRATED
HUMAN-CENTRIC | PARALLEL
Target ID = Target Identification; RWE = Real World Evidence; Lead Opt = Lead Optimization; Reg = Regulatory; Comm= Commercial; Al = Artificial Intelligence
[1] Paul, Steven M., et al. "How to improve R&D productivity: the pharmaceutical industry's grand challenge." Nat Rev Drug Discov 9, 203-214 (Mar 2010). [2]Hughes, James P., et al. "Principles of Early Drug Discovery."
British Journal of Pharmacology 162.6, 1239-1249 (Mar 2011). [3] Konersmann, Todd., et al. "Innovating R&D with the Cloud: Business Transformation Could Require Cloud-Enabled Ecosystems, and Services." Deloitte
Valo Insights, Deloitte Center for Health Solutions, (Dec 2020). [4] See, for example, Seoka, Junhee, et al. "Genomic Responses in Mouse Models Poorly Mimic Human Inflammatory Diseases." PNAS, 110 (9) 3507-3512. (Feb 26,
2013). [5] The Opal platform is designed to reduce time and cost in the drug discovery and development process, which we refer to as the Valo Drug Acceleration Model
2Q21
10View entire presentation